UTEST 2015 cohort startup, Deep Genomics, has closed a $40 million Series B. This brings the company’s total funding to-date to $61 million.
The round was led by Future Ventures and received investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures. The financing will be put toward the development of treatments for rare genetic diseases, in addition to the expansion of Deep Genomics’ AI-based drug discovery platform.
Further details can be found on the BetaKit article.